Sonoma Pharmaceuticals 株価情報 (NASDAQ: SNOA)

最新ニュース Sonoma Pharmaceuticals (NASDAQ:SNOA) 株価情報

Sonoma Pharmaceuticals

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals Inc

By extending their partnership, Redis and UiPath will explore ways to leverage the Redis vector database, Semantic Caching, and Semantic Routing to support <a href="https://www.globenewswire.com/Tracker?data=367r1UrsY_x6VbumJW97L0aBJwkjDn_Hs9m2YDd6_c892FYpUFx6-mURL6ZiXQs0rajK9eHx-r6mKR39o_fxkn_8zWi7r-dN7n985BgmWup6kZV8SX-wltRC3hSYZRQp">UiPath Agent Builder</a>, a secure, simple way to build, test, and launch agents and the agentic automations they are executing. With Redis powering these solutions, UiPath agents will understand the meaning behind user queries, making data access faster and system responses smarter, which delivers greater speed and cost efficiency to enterprise developers looking to take advantage of automation. Additionally, via the utilization of semantic routing, UiPath agents will be able to leverage the best LLM or LLM provider depending on the context, intent, and use-case which the customer is trying to solve.

News

Contracts

General

PATH

Redis And UiPath Have Expanded Their Collaboration Toward Furthering Agentic Automation Solutions For Customers

Needham analyst Ryan MacDonald reiterates Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) with a Buy and maintains $70 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Tempus AI, Maintains $70 Price Target

West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process.
&nbsp;
<ul>
<li>Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this year. West has commenced a search for a successor. Mr. Birkett and West plan for him to remain as CFO until his successor is in place, and as an advisor to West in order to facilitate a seamless transition. &nbsp;</li>
<li>Shane Campbell has been appointed to serve as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025.</li>
</ul>
CFO Transition&nbsp;
"On behalf of all of us at West, I want to thank Bernard for his strong contributions and leadership over the past seven years. He has been an invaluable partner and advisor to me and the entire leadership team," said Eric M. Green, President, Chief Executive Officer and Chair of the Board. "Bernard played a critical role along with the Finance and Global Operations teams, in helping West navigate the challenges of the global pandemic, the complexities of destocking, and the emergence of GLP-1s. He has been instrumental in our continued growth, and I look forward to his support as we search for his successor."
"After great consideration, I have decided to bring my tenure at West to a close in order to pursue new endeavors. It has been an honor to serve as the CFO of West, making a positive difference on patients' lives," Mr. Birkett said. "West has exceptional people, and I want to thank our talented team for all that we have accomplished together."
Mr. Birkett joined West as Senior Vice President and Chief Financial Officer in June 2018. In 2022, he was appointed to the combined role of Chief Financial and Operations Officer. In April 2024, he transitioned back to focusing solely on his responsibilities as Chief Financial Officer. Mr. Birkett's contributions have been pivotal in strengthening West's financial and business profile.
Chief Proprietary Segment Officer Appointment
Mr. Campbell joins West from Carlisle Companies Inc., where he served as Chief Commercial Officer of the Construction Materials business. As an accomplished leader, Mr. Campbell brings extensive global management experience across operations, engineering, commercial and strategy. Over a 20-year career at DuPont, Mr. Campbell served in a number of senior global leadership roles focused in the areas of elastomers, polymers, building materials, chemicals, packaging and safety.
"We are thrilled to welcome Shane to our team at West," said Mr. Green. "His extensive industry experience and strategic vision will be invaluable as we continue to drive our Proprietary Products strategy and ensure West achieves its long-term growth and success."
"I am excited to join West and work alongside such a talented team that is dedicated to improving patient health," said Mr. Campbell. "With a legacy of over a century of innovation, West is well-positioned to sustain its success well into the future, and I look forward to contributing to the tradition of excellence that pervades the Company."

Management

West Pharma CFO Bernard Birkett to Exit in 2025, Successor Search Underway for Seamless Transition

Outlook for the Second Quarter 2025
For the second quarter ending June 30, 2025, FARO currently expects:
<ul>
<li>Revenue in the range of $79 to $87 million</li>
<li>Gross margin in the range of 56.5% to 58.0%. Non-GAAP gross margin in the range of 57.0% to 58.5%</li>
<li>Operating expenses in the range of $45.0 to $47.0 million. Non-GAAP operating expenses in the range of $38.5 to $40.5 million</li>
<li>Net (loss) income per share in the range of ($0.20) to $0.00. Non-GAAP net income per share in the range of $0.20 to $0.40.</li>
</ul>

Guidance

FARO

Faro Technologies Sees Q2 2025 Adj EPS $0.20-$0.40 vs $0.20 Est; Sees Sales $79M-$87M vs $82.83M Est

PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) affirms FY2025 Adj EPS guidance from $1.48-$1.52 to $1.48-$1.52 vs $1.50 analyst estimate..

PG&E Affirms FY2025 Adj EPS Guidance of $1.48-$1.52 vs $1.50 Est

PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) lowers FY2025 GAAP EPS guidance from $1.30-$1.36 to $1.29-$1.35 vs $1.44 analyst estimate..

PG&E Lowers FY2025 GAAP EPS Guidance from $1.30-$1.36 to $1.29-$1.35 vs $1.44 Est

Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) reported quarterly earnings of $0.84 per share which missed the analyst consensus estimate of $0.92 by 8.7 percent. This is a 4.55 percent decrease over earnings of $0.88 per share from the same period last year. The company reported quarterly sales of $3.91 billion which missed the analyst consensus estimate of $3.93 billion by 0.67 percent. This is a 7.04 percent increase over sales of $3.65 billion the same period last year.

Earnings

Earnings Misses

Xcel Energy Q1 Adj. EPS $0.84 Misses $0.92 Estimate, Sales $3.91B Miss $3.93B Estimate

Faro Technologies Q1 2025 Adj. EPS $0.33 May Not Be Comparable To $0.16 Estimate, Sales $82.86M Beat $80.25M Estimate

WIIM

PepsiCo shares are trading lower after the company reported mixed Q1 results and issued FY25 EPS guidance below estimates. The company indicated it sees more volatility and uncertainty related to trade, which it expects to increase supply chain costs.

For the full year, the Company anticipates delivering between 5,000 and 5,500 homes at an average sales price between $665,000 and $675,000. The Company expects homebuilding gross margin percentage to be in the range of 20.5% and 22.0% for the full year and anticipates its SG&amp;A expense as a percentage of home sales revenue will be in the range of 11.5% and 12.5%. Finally, the Company expects its effective tax rate for the full year to be approximately 27.0%

Tri Pointe Home For 2025 Anticipates Delivering Between 5000-5,500 Homes At An Average Sales Price Between $665K-$675K; Sees Homebuilding Gross Margins Between 20.5%–22%

A semiconductor expert on AlphaSense broke down the industry&#8217;s shifting dynamics with tariffs, trade wars, and other geopolitical uncertainties. While not named by the platform, the expert drew clear lines between those who are poised to win big amid this chaos and those who stand to lose.
What Happened: On Wednesday, AlphaSense, a market intelligence platform that helps analysts and researchers meet subject-matter experts, shared the transcript of one such interaction between an analyst and an expert in the semiconductor industry on its X account.
The expert, who previously worked for Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), says the tariffs will hurt all technology companies across the board. The reason for this, they say, is the &#8220;potential erosion of demand,&#8221; as tariffs have an inflationary effect, impacting consumer purchasing power.
See More: <a href="https://www.benzinga.com/news/25/04/44969920/its-not-going-to-end-well-former-sec-chair-gensler-says-chinese-are-tough-negotiators-who-believe-they-can-outwait-us-policy-volatility">&#8216;It&#8217;s Not Going To End Well&#8217;—Former SEC Chair Gensler Says Chinese Are &#8216;Tough Negotiators&#8217; Who Believe They Can Outwait US Policy Volatility</a>
They, however, believe that companies like the Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) are at a much more favorable position relative to peers. This is because TSMC manufactures 90% of the world&#8217;s advanced chips, and is thus a beneficiary of President Donald Trump&#8217;s recent exemptions on electronics imports. 
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Semiconductor industry expert explains the effects of tariffs and who the winners and losers might be in the industry ( <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a>, <a href="https://twitter.com/search?q=%24TSM&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSM</a>, <a href="https://twitter.com/search?q=%24ASML&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ASML</a>): &#8211; The expert expects the tariffs to impact technology companies across the board negatively. The biggest impact he sees is the potential… <a href="https://t.co/AIU3RSd9ZJ">pic.twitter.com/AIU3RSd9ZJ</a>
&mdash; AlphaSense (@AlphaSenseInc) <a href="https://twitter.com/AlphaSenseInc/status/1914665679178866924?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Because China considers Taiwan a part of its territory, it hasn't imposed tariffs on imports from the island, a factor that further benefits TSMC. With no manufacturing facilities in the U.S., the chipmaker is uniquely positioned to serve customers in China, the U.S., and globally, with minimal trade barriers.
Besides this, the expert sees the deterioration of relationships between the U.S. and the E.U. as an advantage for fab equipment maker ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>), allowing it to freely sell to customers in China, from where it already derives <a href="https://benzinga.com/25/03/44136859/asml-faces-uncertainty-as-us-sanctions-on-china-cut-demand-stock-down-24-in-12-months">close to 40%</a> of its sales annually.
The expert views the tariffs as a net negative for Nvidia, particularly in light of China's new export restrictions, which are expected to create a bottleneck for the company's high-end chips. Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) is also seen as vulnerable, with them suggesting that it stands to lose on both fronts of the escalating trade tensions.
Why It Matters: There has been a flurry of activity in the semiconductor industry in recent weeks, with major players like TSMC announcing <a href="https://benzinga.com/25/03/44084767/taiwan-semiconductor-weighs-100-billion-us-investment-as-chip-war-heats-up">plans to invest $100 billion</a> to begin chip production within the United States. 
China <a href="https://benzinga.com/markets/equities/25/02/43966206/china-warns-tsmc-could-become-united-states-semiconductor-manufacturing-co-as-trump-pushes-us-chipmaking">saw this coming</a> early this year, with Zhu Fenglian, spokesperson for Beijing's Taiwan Affairs Office, taking a jab at TSMC, warning that it could soon be called the &#8220;United States Semiconductor Manufacturing Co.,&#8221; suggesting that the Taiwanese government was selling out domestic companies for political backing from the U.S. government. 
While Nvidia remains caught in the crosshairs between China and the United States, some analysts are doubling down on the stock, despite the new AI diffusion rules and H20 export ban. According to BoFA analyst Vivek Arya, the <a href="https://benzinga.com/analyst-ratings/price-target/25/04/44934100/analyst-sticks-with-nvidia-despite-fallout-from-china-curbs">company&#8217;s global footprint</a>, alongside the growing sales of Blackwell Ultra GPUs, should help offset any major impact.
Price Action: Shares of Nvidia were up 3.86% yesterday, trading at $102.71, followed by TSMC at 157.81, up 4.20%. ASMV Holding and Intel were up 3.02% and 5.54%, respectively.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="139" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24035627/Screenshot-2025-04-24-at-1.26.13-PM-1024x139.png" alt="" class="wp-image-885889" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24035627/Screenshot-2025-04-24-at-1.26.13-PM-1024x139.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24035627/Screenshot-2025-04-24-at-1.26.13-PM-300x41.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24035627/Screenshot-2025-04-24-at-1.26.13-PM-768x104.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24035627/Screenshot-2025-04-24-at-1.26.13-PM-1536x208.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24035627/Screenshot-2025-04-24-at-1.26.13-PM.png 1592w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Nvidia scores high on growth and quality, but low on momentum and value, according to Benzinga&#8217;s Edge Stock Rankings. What about TSMC, Intel, and ASML? Sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge</a> to find out more. 
Read More: <a href="https://www.benzinga.com/government/regulations/25/04/44971572/nvidia-chip-ban-wont-stop-chinas-ai-momentum-say-analysts-blocking-h20-would-hand-market-to-huawei-amid-trump-era-export-crackdown">Nvidia Chip Ban Won&#8217;t Stop China&#8217;s AI Momentum, Say Analysts — Blocking H20 Would Hand Market To Huawei Amid Trump-Era Export Crackdown</a>
Image Via Shutterstock

Equities

Markets

ASML

INTC

NVDA

TSMC, ASML May Win The Chip War, Says Expert, But Nvidia And Intel Could Feel The Heat From Trump Tariffs

West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) lowers FY2025 GAAP EPS guidance from $5.97-$6.17 to $5.86-$6.06 vs $6.03 analyst estimate..

West Pharmaceutical Servs Lowers FY2025 GAAP EPS Guidance from $5.97-$6.17 to $5.86-$6.06 vs $6.03 Est

West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) raises FY2025 Adj EPS guidance from $6.00-$6.20 to $6.15-$6.35 vs $6.14 analyst estimate. Raises FY2025 sales outlook from $2.88 billion-$2.90 billion to $2.94 billion-$2.98 billion vs $2.90 billion estimate.

West Pharmaceutical Servs Raises FY2025 Adj EPS Guidance from $6.00-$6.20 to $6.15-$6.35 vs $6.14 Est; Raises FY2025 Sales Guidance from $2.88B-$2.90B to $2.94B-$2.98B vs $2.90B Est

Outlook
For the second quarter, the Company anticipates delivering between 1,100 and 1,200 homes at an average sales price between $680,000 and $690,000. The Company expects homebuilding gross margin percentage to be in the range of 21.5% to 22.5% for the second quarter and anticipates its SG&amp;A expense as a percentage of home sales revenue will be in the range of 12.5% to 13.5%. Finally, the Company expects its effective tax rate for the second quarter to be approximately 27.0%.

Tri Pointe Home For Q2 Anticipates Delivering Between 1,100-1,200 Homes At An Average Sales Price Between $680K-$690K; Sees Homebuilding Gross Margins Between 21.5%–22.5

UBS&nbsp;analyst&nbsp;David Vogt&nbsp;has&nbsp;adjusted the price target for&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares, lowering it from $236 to $210,&nbsp;while retaining a &#8216;Neutral&#8217; rating. This adjustment has been made in anticipation of widespread tariffs.
What Happened: Vogt observed that Apple seems to have expedited the shipment of around one million iPhones, leading to a year-over-year rise in iPhone revenue for the March quarter, even though demand remained stable or only slightly higher, <a href="https://in.investing.com/news/analyst-ratings/ubs-cuts-apple-stock-price-target-to-210-from-236-93CH-4787262">reported </a>Investing.com.
Given the rise in iPhone shipments and the notable depreciation of the U.S. dollar against global currencies during the quarter, the analyst updated the revenue and EPS projections for March 2025. Consequently, UBS has raised its revenue estimate for Apple's March quarter by about 2%, adjusting the forecast to $95.5 billion from the earlier $93.5 billion.
Meanwhile, MoffettNathanson Research attributed the pressure on Apple stock to a mix of geopolitical shifts, rising production costs from tariffs, and mounting recession risks. The firm reiterated its &#8220;Sell&#8221; rating and cut its price target for Apple shares from $184 to $141. "Paying a fortune in tariffs or paying a fortune in rearchitecting supply chains only to finish with much higher costs is a lose-lose choice," MoffettNathanson analysts said.
The report highlighted that Apple imports from China will continue to be subject to 20% tariffs—an amount that would have seemed unimaginable just a month ago.
Besides tariffs, MoffettNathanson also cites Apple&#8217;s slow progress on the AI front and lack of exciting offerings including the foldable iPhones as reasons to be pessimistic. 
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/44946477/as-long-as-you-had-a-pulse-youd-be-hired-says-a-worker-longing-for-another-great-resignation-with-ridiculous" target="_blank" rel="noreferrer noopener">&#8216;As Long As You Had A Pulse You&#8217;d Be Hired,&#8217; Says A Worker, Longing For Another Great Resignation With &#8216;Ridiculous Salaries&#8217; And Remote Jobs</a>
Why It Matters: Apple has been facing challenges on multiple fronts. The company was recently fined <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act">nearly $800 million</a> by the European Union for violating the bloc&#8217;s Digital Markets Act. The fine was imposed for restricting app developers from informing users about alternative sales or promotions outside the App Store and for limiting access to competing app stores on Apple devices.
Furthermore, CNBC commentator Jim Cramer expressed concerns that the stringent China policy of the Trump administration is negatively impacting <a href="https://www.benzinga.com/markets/25/04/44916134/nvidia-and-apple-caught-in-the-crosshairs-of-trumps-trade-war-with-china-says-jim-cramer-until-trump-became-president">tech giants </a>like Apple. These factors, combined with the anticipated tariffs, are likely to continue exerting pressure on Apple&#8217;s stock.
On the other hand, Goldman Sachs analyst Michael Ng <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44961882/iphone-resecue-apple-tariff-worries">maintained </a>a &#8216;Buy&#8217; Rating on the stock but lowered its price target. He stated that the reciprocal tariff exemptions on smartphones and PCs announced on April 11 are likely to shield Apple from significant short-term effects.
Benzinga's Edge Rankings&nbsp;highlight strong momentum and quality rankings for Apple in the 69th and 85th percentiles, respectively. Curious how other stocks stack up?&nbsp;<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">Click here</a>&nbsp;to uncover growth and momentum scores for top stocks.
Apple stock declined more than 7% over the past month, according to data from <a href="http://pro.benzinga.com">Benzinga Pro.</a>
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/04/44970313/missed-fortune-trump-trader-loses-45-million-profit-opportunity-before-dinner-announcement" target="_blank" rel="noreferrer noopener">Trader Dumps TRUMP Tokens Before Presidential Dinner Revelation: Meal Cost Early Seller $4.5 Million</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

AAPL

AAPL Stock Faces Analyst Downgrades On Looming Tariffs, Supply Chain Pressures: 'A Lose-Lose Choice'

Apogee Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) is looking for FY2026 GAAP EPS of $2.54-$3.19 vs $4.31 analyst estimate..

APOG

Apogee Enterprises Sees FY2026 GAAP EPS $2.54-$3.19 vs $4.31 Est

FCFS

FirstCash Sees Strong 2025 Ahead, Backed By Robust Q1, Rising Pawn Loan Demand, Asset Growth, And Store Expansions

Apogee Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) is looking for FY2026 Adj EPS of $3.55-$4.10 vs $4.33 analyst estimate. sees sales of $1.370 billion-$1.430 billion vs $1.37 billion analyst estimate.

Apogee Enterprises Sees FY2026 Adj EPS $3.55-$4.10 vs $4.33 Est; Sees Sales $1.370B-$1.430B vs $1.37B Est

Texas Instruments shares are trading higher after the company reported Q1 financial results and beat its EPS and sales estimates. Additionally, the company issued Q2 sales guidance above estimates.

LRCX

Lam Research shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 guidance above estimates.

Press Releases

Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada

Events

Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results

Legal

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel

Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results

Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando

Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

Comments

Sonoma Pharmaceuticals

ニュース

最新ニュース Sonoma Pharmaceuticals (NASDAQ:SNOA) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル